A phase I study of concomitant CPT-11 (C) and 5FU (F) combination: Preliminary results

被引：0
|
作者：
Rixe, O
Benhammouda, A
Farabos, C
Borel, C
Petit, T
Auclerc, G
Coeffic, D
Bastian, G
Grossin, F
Paraiso, D
Grapin, JP
Nizri, D
Weil, M
Bismuth, H
Mahjoubi, M
Khayat, D
机构：
[1] SALPETRIERE HOSP,SOMPS,PARIS,FRANCE
[2] HOP PAUL BROUSSE,VILLEJUIF,FRANCE
来源：
EUROPEAN JOURNAL OF CANCER | 1995年 / 31A卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：955 / 955
页数：2
相关论文
共 50 条
  • [21] Randomized phase 3 trial of irinotecan (CPT-11)+5FU/folinic acid (FA) vs CDDP+5FU in 1st-line advanced gastric cancer patients
    Dank, M
    Zaluski, J
    Barone, C
    Valvere, V
    Peschel, C
    Wenczl, M
    Goker, E
    Risse, ML
    Awad, L
    Bugat, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 308S - 308S
  • [22] Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study.
    Creaven, PJ
    Javle, MM
    Pendyala, L
    Smith, P
    Noel, DC
    Iyer, RV
    Lawrence, DD
    Rustum, YM
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 157S - 157S
  • [23] Phase I and pharmacokinetic study of irinotecan (CPT-11) administered with cyclosporine A (CSA).
    Fagbemi, S
    Ratain, MJ
    Iyer, L
    Mani, S
    Vogelzang, NJ
    Wang, X
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 163 - 163
  • [24] Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU):: A phase II study
    Antón, A
    Aranda, E
    Carrato, A
    Marcuello, E
    Massutti, B
    Cervantes, A
    Abad, A
    Sastre, J
    Fenández-Martos, C
    Gallén, M
    Díaz-Rubio, E
    Huarte, L
    Balcells, M
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2003, 25 (08): : 639 - 643
  • [25] Folinic acid (FA) and 5-fluorouracil (FU) alone or with irinotecan (CPT-11) for advanced colorectal cancer (ACC): Preliminary results of a randomized phase II trial
    Maiello, E
    Giuliani, F
    Gebbia, V
    Cigolari, S
    Fortunato, S
    Paoletti, G
    Borsellino, N
    Lopez, M
    Gebbia, N
    Colucci, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S71 - S71
  • [26] A phase II study of CPT 11 (irinotecan) in refractory to 5FU colorectal cancer with curative treatment of delayed diarrhea by Acetorphan
    Merrouche, Y
    Bugat, R
    Brunet, R
    Seitz, JF
    Conroy, T
    Fabre, V
    Namer, M
    Piolat, V
    Mahjoubi, M
    Droz, JP
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 759 - 759
  • [27] A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma
    Gennatas, C.
    Papaxoinis, G.
    Michalaki, V.
    Mouratidou, D.
    Andreadis, Ch.
    Tsavaris, N.
    Pafiti, A.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 (05) : 538 - 544
  • [28] 5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayar, C.
    Piedbois, P.
    Culine, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] A bi-weekly schedule of irinotecan (CPT-11) and 5-fluorouracil (5-FU) in advanced colorectal cancer (ACRC): Phase I study.
    Morese, R
    Ricevuto, U
    Cannita, K
    Antonini, CGC
    Lanfiuti, BP
    Trapasso, T
    Porzio, G
    Marchetti, P
    Ficorella, C
    ANNALS OF ONCOLOGY, 2000, 11 : 71 - 71
  • [30] Phase II trial of irinotecan (CPT-11) in patients with 5-FU resistant advanced colorectal cancer
    Vicent, JM
    Aparicio, J
    Lizon, J
    Molins, C
    Alonso, JD
    Gimenez-Arnau, JM
    Camps, C
    Segura, A
    Rizo, A
    Xarles, J
    ANNALS OF ONCOLOGY, 1998, 9 : 44 - 45
12345